Kralovics R
Center for Molecular Medicine (CeMM), Austrian Academy of Sciences, Vienna, Austria.
Leukemia. 2008 Oct;22(10):1841-8. doi: 10.1038/leu.2008.233. Epub 2008 Aug 28.
Oncogenic mutations in JAK2 and MPL genes have recently been identified in myeloproliferative neoplasms (MPNs). In addition to these mutations, cytogenetic aberrations are frequently present at diagnosis but their role in the pathogenesis remains unclear. Two models of MPN pathogenesis have recently emerged based on either a single-hit or a multi-hit concept. The first model proposes that the acquisition of JAK2 mutations is the disease-initiating event, causing both the onset of disease phenotype and establishment of clonal hematopoiesis. The second model postulates the existence of 'pre-JAK2' mutations that establish clonal hematopoiesis before acquisition of JAK2 mutations and onset of disease phenotype. In this review, the two models have been critically evaluated in the context of the latest findings. At present, neither of the two models can be universally applied to all MPN patients due to their genetic heterogeneity. It is likely that the disease pathogenesis in some patients follows the first, and in other patients, the second model. Thus, the somatic mutations in MPN do not seem to be acquired in a predetermined order as seen in other malignancies, but occur randomly. Furthermore, the role of uniparental disomy in MPN and certain aspects of MPN therapy are discussed.
近期在骨髓增殖性肿瘤(MPN)中发现了JAK2和MPL基因的致癌突变。除了这些突变外,细胞遗传学异常在诊断时也经常出现,但其在发病机制中的作用仍不清楚。基于单次打击或多次打击概念,最近出现了两种MPN发病机制模型。第一种模型提出,JAK2突变的获得是疾病起始事件,导致疾病表型的出现和克隆性造血的建立。第二种模型假定存在“前JAK2”突变,这些突变在获得JAK2突变和疾病表型出现之前就建立了克隆性造血。在这篇综述中,结合最新研究结果对这两种模型进行了批判性评估。目前,由于其基因异质性,这两种模型都不能普遍适用于所有MPN患者。某些患者的疾病发病机制可能遵循第一种模型,而其他患者则遵循第二种模型。因此,MPN中的体细胞突变似乎不像在其他恶性肿瘤中那样按预定顺序获得,而是随机发生的。此外,还讨论了单亲二体在MPN中的作用以及MPN治疗的某些方面。